Nectar Lifesciences Limited (NSE:NECLIFE)
India · Delayed Price · Currency is INR 11.65
-0.28 (-2.35%)
Sep 11, 2026, 3:29 PM IST
Nectar Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 0.15 | - | - | 16,841 | 15,237 | 16,688 |
Other Revenue | - | - | - | 4.84 | 0.25 | 0.25 |
| 0.15 | - | - | 16,846 | 15,237 | 16,689 | |
Revenue Growth | -100.00% | - | - | 10.56% | -8.70% | 8.13% |
Cost of Revenue | 0.14 | - | - | 12,195 | 11,593 | 12,231 |
Gross Profit | 0.01 | - | - | 4,650 | 3,644 | 4,457 |
Selling, General & Admin | 29.56 | 29.44 | 0.97 | 865.6 | 796.01 | 763.07 |
Other Operating Expenses | 730.31 | 1,079 | 0.66 | 2,249 | 2,309 | 2,109 |
Operating Expenses | 763.53 | 1,113 | 7.81 | 3,722 | 3,696 | 3,441 |
Operating Income | -763.52 | -1,113 | -7.81 | 928.4 | -51.72 | 1,016 |
Interest Expense | -362.82 | -1.47 | - | -896.23 | -827.98 | -699.44 |
Interest & Investment Income | - | 70.4 | 14.51 | 123.9 | 17.26 | 18.84 |
Currency Exchange Gain (Loss) | - | -359.78 | - | 97.5 | 98.78 | 4.68 |
Other Non Operating Income (Expenses) | - | 2.4 | 3.67 | -72.68 | -65.67 | -93.34 |
EBT Excluding Unusual Items | -1,126 | -1,401 | 10.37 | 180.89 | -829.33 | 246.71 |
Gain (Loss) on Sale of Investments | - | 520.95 | 0.35 | 1.8 | 1.05 | 0.03 |
Gain (Loss) on Sale of Assets | - | 1.6 | - | - | 404.08 | 94.07 |
Pretax Income | -1,126 | -878.79 | 10.72 | 182.69 | -424.2 | 340.81 |
Income Tax Expense | -394.8 | -305.32 | 3.75 | 132.74 | -182.37 | 90.34 |
Earnings From Continuing Operations | -731.54 | -573.47 | 6.97 | 49.95 | -241.83 | 250.47 |
Earnings From Discontinued Operations | -1,719 | -2,355 | -1,144 | - | - | - |
Net Income | -2,451 | -2,929 | -1,137 | 49.95 | -241.83 | 250.47 |
Net Income to Common | -2,451 | -2,929 | -1,137 | 49.95 | -241.83 | 250.47 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 211 | 219 | 224 | 224 | 224 | 224 |
Shares Outstanding (Diluted) | 211 | 219 | 224 | 224 | 224 | 224 |
Shares Change | -5.35% | -2.57% | - | - | - | - |
EPS (Basic) | -11.60 | -13.40 | -5.07 | 0.22 | -1.08 | 1.12 |
EPS (Diluted) | -11.60 | -13.40 | -5.07 | 0.22 | -1.08 | 1.12 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -3,610 | 1,256 | 1,953 | 1,036 | 700.35 |
Free Cash Flow Per Share | - | -16.52 | 5.60 | 8.71 | 4.62 | 3.12 |
Gross Margin | 5.52% | - | - | 27.61% | 23.92% | 26.71% |
Operating Margin | -526564.14% | - | - | 5.51% | -0.34% | 6.09% |
Profit Margin | -1690054.48% | - | - | 0.30% | -1.59% | 1.50% |
Free Cash Flow Margin | - | - | - | 11.59% | 6.80% | 4.20% |
EBITDA | -634.45 | -884.86 | 616.08 | 1,536 | 539.47 | 1,586 |
EBITDA Margin | - | - | - | 9.12% | 3.54% | 9.50% |
D&A For EBITDA | 129.07 | 228.03 | 623.89 | 607.18 | 591.19 | 569.68 |
EBIT | -763.52 | -1,113 | -7.81 | 928.4 | -51.72 | 1,016 |
EBIT Margin | - | - | - | 5.51% | -0.34% | 6.09% |
Effective Tax Rate | - | - | 34.98% | 72.66% | - | 26.51% |
Revenue as Reported | 123.44 | 92.91 | 18.78 | 16,987 | 15,668 | 16,802 |
Advertising Expenses | - | 1.24 | - | - | - | - |